small molecule

VTAMA

TAPINAROF

Loss of exclusivityDecember 2039latest FDA-listed patent expiry
CompanyOrganonView the full company profile on CliffBio

Drug detail

Brand nameVTAMA
Active ingredientTAPINAROF
Strength1%
Dosage formCREAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalMay 2022
Marketing statusRX

Listed patents

PatentExpiresType
12569453December 2039use U-4048
11938099November 2039use U-4048
11590088November 2039use U-2625
11497718November 2039use U-4048
10647649November 2038substance
11597692November 2038substance, product
10195160May 2036product
10426743May 2036use U-2625
11617724May 2036product
11458108May 2036product
11622945May 2036product
11612573May 2036use U-2625

Regulatory exclusivity

CodeExpires
I-956December 2027
NCEMay 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Not found